NASDAQ:PHAT

Phathom Pharmaceuticals Competitors

$38.00
-0.49 (-1.27 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.09
Now: $38.00
$38.48
50-Day Range
$35.83
MA: $42.58
$48.68
52-Week Range
$27.47
Now: $38.00
$64.54
Volume46,782 shs
Average Volume103,270 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Competitors

Phathom Pharmaceuticals (NASDAQ:PHAT) Vs. AVIR, BHVN, SAGE, HCM, EBS, and ARNA

Should you be buying PHAT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Phathom Pharmaceuticals, including Atea Pharmaceuticals (AVIR), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), and Arena Pharmaceuticals (ARNA).

Atea Pharmaceuticals (NASDAQ:AVIR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Atea Pharmaceuticals and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Phathom PharmaceuticalsN/A-88.73%-69.04%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Atea Pharmaceuticals and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Phathom Pharmaceuticals10402.60

Atea Pharmaceuticals presently has a consensus target price of $69.3333, indicating a potential upside of 25.35%. Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Phathom Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 39.8% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biohaven Pharmaceutical (NYSE:BHVN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Profitability

This table compares Biohaven Pharmaceutical and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Biohaven Pharmaceutical and Phathom Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Phathom Pharmaceuticals10402.60

Biohaven Pharmaceutical currently has a consensus price target of $96.4545, indicating a potential upside of 36.29%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Phathom Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.49
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72

Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Biohaven Pharmaceutical on 7 of the 11 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Sage Therapeutics and Phathom Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million634.64$-680,240,000.00($13.38)-5.58
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72

Phathom Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Sage Therapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Phathom Pharmaceuticals10402.60

Sage Therapeutics currently has a consensus price target of $87.0625, indicating a potential upside of 16.58%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Sage Therapeutics.

Volatility & Risk

Sage Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Profitability

This table compares Sage Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Summary

Phathom Pharmaceuticals beats Sage Therapeutics on 7 of the 13 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Hutchison China MediTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72
Hutchison China MediTech$204.89 million20.81$-106,020,000.00($0.80)-36.63

Hutchison China MediTech has higher revenue and earnings than Phathom Pharmaceuticals. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Hutchison China MediTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phathom Pharmaceuticals10402.60
Hutchison China MediTech00203.00

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Hutchison China MediTech has a consensus target price of $40.00, indicating a potential upside of 36.52%. Given Phathom Pharmaceuticals' higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Hutchison China MediTech.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phathom PharmaceuticalsN/A-88.73%-69.04%
Hutchison China MediTechN/AN/AN/A

Phathom Pharmaceuticals (NASDAQ:PHAT) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Emergent BioSolutions' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72
Emergent BioSolutions$1.11 billion3.66$54.50 million$2.9126.07

Emergent BioSolutions has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Emergent BioSolutions, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phathom Pharmaceuticals10402.60
Emergent BioSolutions02502.71

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Emergent BioSolutions has a consensus target price of $109.8333, indicating a potential upside of 44.78%. Given Emergent BioSolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Phathom Pharmaceuticals.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phathom PharmaceuticalsN/A-88.73%-69.04%
Emergent BioSolutions12.50%26.68%12.70%

Summary

Emergent BioSolutions beats Phathom Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.72
Arena Pharmaceuticals$806.43 million4.85$397.55 million$7.698.42

Arena Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phathom Pharmaceuticals10402.60
Arena Pharmaceuticals001503.00

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 41.75%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Phathom Pharmaceuticals.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phathom PharmaceuticalsN/A-88.73%-69.04%
Arena PharmaceuticalsN/A-33.17%-30.41%

Summary

Arena Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 12 factors compared between the two stocks.


Phathom Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.58 billionN/A0.00Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.39 billionN/A-5.77Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.36 billion$6.87 million-7.22Analyst Report
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.04 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$3.91 billion$806.43 million-9.17
LEGN
Legend Biotech
1.2$27.81-2.3%$3.67 billion$64.39 million0.00Decrease in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.67 billionN/A-21.35News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.44 billion$4.31 million-1.66Increase in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.41 billion$114.62 million-7.53
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.31 billion$306.98 million-6.74
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.27 billion$339.08 million-11.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.18 billion$136.47 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.11 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.04 billionN/A-56.03
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$2.99 billion$1.17 billion-40.83
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.98 billion$421.03 million23.93Analyst Revision
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.94 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.92 billion$80.43 million105.58Decrease in Short Interest
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.30 billion$429.76 million-116.78
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.29 billion$156.70 million-28.28News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.21 billion$963.01 million13.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.16 billion$15 million-15.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$1.99 billion$410,000.00-6.07
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$1.91 billionN/A-26.43Increase in Short Interest
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62-0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53-3.7%$1.88 billion$103.54 million-18.44News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73-2.8%$1.87 billion$16.98 million-37.01Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16-2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89-6.6%$1.82 billion$256.58 million-7.62
MacroGenics logo
MGNX
MacroGenics
1.4$30.07-3.6%$1.80 billion$64.19 million-9.61Decrease in Short Interest
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.